Emergent BioSolutions
Emergent BioSolutions is dedicated to developing, manufacturing, and delivering medical countermeasures that address public health threats. With a mission to protect and enhance life, the company focuses on innovative vaccines and therapeutics to combat critical health challenges, including the ongoing opioid crisis.
Industries
Nr. of Employees
Very Large (1000+)
Emergent BioSolutions
Patents
Products
Intranasal emergency antidote formulation
A consumer‑oriented intranasal formulation of an opioid antagonist intended for rapid administration by lay responders to reverse opioid‑induced respiratory depression.
Community harm‑reduction kit
Preassembled kits for community distribution that include an emergency antidote dose, point‑of‑use drug‑checking materials, secure storage guidance, and concise user instructions and referral resources.
Intranasal emergency antidote formulation
A consumer‑oriented intranasal formulation of an opioid antagonist intended for rapid administration by lay responders to reverse opioid‑induced respiratory depression.
Community harm‑reduction kit
Preassembled kits for community distribution that include an emergency antidote dose, point‑of‑use drug‑checking materials, secure storage guidance, and concise user instructions and referral resources.
Expertise Areas
- Expanded access and compassionate use operations
- Clinical trial referral and investigator regulatory support
- Community distribution and harm‑reduction program design
- First responder and co‑responder program development with peer integration
Key Technologies
- Intranasal drug delivery for emergency use
- Point‑of‑use drug‑checking (test strips and portable analyzers)
- Public‑access dispensing cabinets and grab‑and‑go dispensers
- Human factors and usability testing methods for consumer medical devices
Key People
News & Updates
Emergent BioSolutions announced that brincidofovir will be included in a clinical trial conducted by PANTHER, evaluating its safety and efficacy in treating mpox virus.
Emergent BioSolutions reported financial results for the third quarter ended September 30, 2024.
Emergent BioSolutions announced the appointment of Simon Lowry, M.D., as chief medical officer, effective November 18.
Emergent BioSolutions announced that brincidofovir will be included in a clinical trial conducted by PANTHER, evaluating its safety and efficacy in treating mpox virus.
Emergent BioSolutions reported financial results for the third quarter ended September 30, 2024.
Emergent BioSolutions announced the appointment of Simon Lowry, M.D., as chief medical officer, effective November 18.